Tony Matzouranis
Corporate Officer/Principal bij BELLUS HEALTH
Actieve functies van Tony Matzouranis
| Bedrijven | Functie | Begin | Einde |
|---|---|---|---|
| BELLUS HEALTH | Corporate Officer/Principal | 01-01-2010 | - |
Loopbaan van Tony Matzouranis
Eerdere bekende functies van Tony Matzouranis
| Bedrijven | Functie | Begin | Einde |
|---|---|---|---|
| THALLION PHARMACEUTICALS INC. | Corporate Officer/Principal | 01-01-2007 | 01-02-2010 |
Opleiding van Tony Matzouranis
| Université du Québec à Montréal | Graduate Degree |
Statistieken
Internationaal
| Canada | 4 |
Operationeel
| Corporate Officer/Principal | 2 |
| Graduate Degree | 1 |
Sectoraal
| Health Technology | 3 |
| Consumer Services | 2 |
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Verwante bedrijven
| Bedrijven in privébezit | 2 |
|---|---|
BELLUS Health, Inc.
 BELLUS Health, Inc. Pharmaceuticals: MajorHealth Technology BELLUS Health, Inc. is a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of cough hypersensitivity and other hypersensitization disorders. Its product BLU-5937, is being developed for the treatment of chronic cough and chronic pruritus, or chronic itch. The company was founded on June 17, 1993 and is headquartered in Laval, Canada. | Health Technology |
Thallion Pharmaceuticals, Inc.
 Thallion Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Thallion Pharmaceuticals, Inc. is a biotechnology company focused on developing new pharmaceutical products in the areas of infectious disease and oncology. Its products are Shigamabs, a dual antibody product for the treatment of Shigatoxin-producing E. coli bacterial infections and TLN-4601, a proprietary first in class small molecule with potential efficacy in multiple oncology indications. The company was founded in January 1998 and is headquartered in Dorval, Canada. | Health Technology |
- Beurs
- Insiders
- Tony Matzouranis
- Ervaring
